Extracted from this filing and checked against the source text.
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.9
Sonoma Pharmaceuticals, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
- Exchange
- nasdaq
- Notice
- noncompliance notice
- Deficiency
- minimum bid price
- Rules
- 5550(a)(2), 5810(c)(3)(A)
Exact text from the filing
September 22, 2023, we received a letter from the Listing Qualifications staff of The Nasdaq Stock Market LLC, notifying us that, for the previous 30 consecutive business days, we have failed to comply with Nasdaq Listing Rule 5550(a)(2), which requires us to maintain a minimum bid price of $1 per share for our common stock. In accordance with Listing Rule 5810(c)(3)(A), Nasdaq has granted us a period of 180 calendar days, or until March 20, 2024, to regain compliance with the Rule. We may regain compliance with the Rule at any time during this compliance period if the minimum bid price for ou
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Sonoma Pharmaceuticals, Inc. shareholders approved Election of One Class III Director at the 2023-09-28 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-09-28
Exact text from the filing
Proposal 1 – Election of One Class III Director Mr. Jerry McLaughlin was duly elected as our Class III director. The results of the election were as follows: NOMINEE FOR WITHHELD Jerry McLaughlin 552,672 306,238
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Sonoma Pharmaceuticals, Inc. shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2023-09-28 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-09-28
Exact text from the filing
Proposal 3 – Ratification of the Appointment of Independent Registered Public Accounting Firm Our stockholders voted upon and approved the ratification of the appointment of Frazier & Deeter, LLC as our independent registered public accounting firm for the fiscal year ending March 31, 2024. The votes on this proposal were as follows: FOR AGAINST ABSTAIN 2,560,351 41,495 3,765
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Sonoma Pharmaceuticals, Inc. shareholders rejected Advisory Vote to Approve Executive Compensation at the 2023-09-28 meeting.
- Proposal
- say on pay
- Outcome
- failed
- Meeting
- 2023-09-28
Exact text from the filing
Proposal 2 – Advisory Vote to Approve Executive Compensation Our stockholders voted upon and did not approve, by non-binding advisory vote, the compensation of our named executive officers for the year ended March 31, 2023, as described in our proxy statement dated July 27, 2023. The votes on this proposal were as follows: FOR AGAINST ABSTAIN 560,065 290,657 8,188
View on SEC.gov